Patents by Inventor Simon L. Goodman

Simon L. Goodman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Soluble recombinant ??adhesion receptor
    Patent number: 8067197
    Abstract: The invention relates to a novel purified recombinant ?V?3 adhesion receptor which shows an unimpaired ligand binding activity, and a process for preparing said soluble non-membrane bound receptor in excellent yields by recombinant techniques using a baculovirus-insect cell expression system. The so-synthesized soluble receptor may be used very easily as screening tool for new therapeutic compounds which may inhibit the natural ?V?3 adhesion receptor. Such therapeutic compounds which can be discovered very easily, fast and without health risk by means of the soluble receptors according to the invention may be, for example, RGD peptides or non-peptidic compounds mimicking the natural ligand epitopes. The invention relates, furthermore, to a corresponding process for preparing recombinant full-length ?V?3 adhesion receptor in excellent yields, additionally using detergents to dissolve the membrane bound receptor from the surface of the host cell.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: November 29, 2011
    Assignee: Merck Patent GmbH
    Inventors: Simon L. Goodman, Beate Diefenbach, Detelv Güssow, Raj Mehta, Eilish Cullen, Alex Brown
  • Bicyclic amino acids
    Patent number: 6559144
    Abstract: Compounds of the formula I in which X, Y, Z, R1, R2, R3, R4, R5, R7, R8, R11, m and n have the meanings stated in claim 1, and their physiologically acceptable salts can be used as integrin inhibitors, in particular for the prophylaxis and treatment of circulatory disorders, for thrombosis, myocardial infarct, coronary heart disease, arteriosclerosis, osteoporosis, for pathological processes maintained or propagated by angiogenesis, and in tumour therapy.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: May 6, 2003
    Assignee: Merck Patent Gesellschaft Mit
    Inventors: Beate Diefenbach, Simon L. Goodman, Joachim März, Peter Raddatz, Friedrich Rippmann, Matthias Wiesner
  • SOLUBLE RECOMBINANT ALPHA BETA ADHESION RECEPTOR
    Publication number: 20020055136
    Abstract: The invention relates to a novel purified recombinant &agr;v&bgr;3 adhesion receptor which shows an unimpaired ligand binding activity, and a process for preparing said soluble non-membrane bound receptor in excellent yields by recombinant techniques using a baculovirus-insect cell expression system. The so-synthesized soluble receptor may be used very easily as screening tool for new therapeutic compounds which may inhibit the natural &agr;v&bgr;3 adhesion receptor. Such therapeutic compounds which can be discovered very easily, fast and without health risk by means of the souluble receptors according to the invention may be, for example, RGD peptides or non-peptidic compounds mimicking the natural ligand epitopes. The invention relates, furthermore, to a corresponding process for preparing recombinant full-length &agr;v&bgr;3 adhesion receptor in excellent yields, additionally using detergents to dissolve the membrane bound receptor from the surface of the host cell.
    Type: Application
    Filed: December 9, 1997
    Publication date: May 9, 2002
    Inventors: SIMON L. GOODMAN, BEATE DIEFENBACH, DETLEF GUESSOW, RAJ J. MEHTA, EILISH CULLEN, ALEX BROWN
  • Bicyclic amino acids
    Publication number: 20010021709
    Abstract: Compounds of the formula I 1
    Type: Application
    Filed: April 26, 2001
    Publication date: September 13, 2001
    Applicant: Merck Patent Gesellschaft mit Beschrankt Patents
    Inventors: Beate Diefenbach, Simon L. Goodman, Joachim Marz, Peter Raddatz, Friedrich Rippmann, Matthias Wiesner